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Abstract
Background: Delay in start of tuberculosis (TB) treatment has an impact at both the individual
level, by increasing the risk of morbidity and mortality, and at the community level, by increasing
the risk of transmission. The aims of this study were to assess the delays in the start of treatment
for TB patients in Oslo/Akershus region, Norway and to analyze risk factors for the delays.
Methods: This study was based on information from the National TB Registry, clinical case notes
from hospitals and referral case notes from primary health care providers. Delays were divided into
patient, health care system and total delays. The association with sex, birthplace, site of the disease
and age group was analyzed by multiple linear regression.
Results: Among the 83 TB patients included in this study, 71 (86%) were born abroad. The median
patient, health care system and total delays were 28, 33 and 63 days respectively, with a range of
1–434 days. In unadjusted analysis, patient delay and health care system delay did not vary
significantly between men and women, according to birthplace or age group. Patients with extra-
pulmonary TB had a significantly longer patient, health care system and total delay compared to
patients with pulmonary TB. Median total delay was 81 and 56 days in the two groups of TB patients
respectively. The health care system delay exceeded the patient delay for those born in Norway.
The age group 60+ years had significantly shorter patient delay than the reference group aged 15–
29 years when adjusted for multiple covariates. Also, in the multivariate analysis patients born in
Norway had significantly longer health care system delay than patients born abroad.
Conclusion: A high proportion of patients had total delays in start of TB treatment exceeding two
months. This study emphasizes the need of awareness of TB in the general population and among
health personnel. Extra-pulmonary TB should be considered as a differential diagnosis in unresolved
cases, especially for immigrants from high TB prevalence countries.
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Background
The tuberculosis (TB) epidemiology in Norway has
changed in the last 30 years. TB is now more likely to
occur among immigrants (median age 31 years) than
among those born in Norway (median age 72 years) [1,2].
The proportion of immigrants in the total population in
2003 was 7.3% [3]. DNA fingerprinting of bacterial strains
indicated a low degree of recent transmission, implying
that the majority of TB cases are due to reactivation of pre-
vious disease [4,5]. Compulsory screening for TB on entry
has been implemented in Norway since the mid-1970s for
persons from high TB prevalence countries who will stay
more than three months [6].
Timely diagnosis of TB and start of treatment are impor-
tant. Delay in start of TB treatment causes patients to have
more advanced disease, more complications, higher mor-
tality and more people being infected from each case [7-
10]. It has been estimated that a patient with untreated
smear-positive pulmonary TB may infect on average more
than 10 patients annually and over 20 during the natural
course of untreated disease until death [11]. To some
extent, smear-negative pulmonary TB may also play a role
in the spread of infection [12,13]. Delay in the start of TB
treatment is relatively common both in high and low TB
prevalence countries [14-19].
Delays are divided into patient delay, health care system
delay and total delay. The health care system delay is
assumed to be a larger problem than patient delay [20].
The problem of delay in the start of TB treatment has been
described in several studies, which have indicated that the
index of suspicion for diagnosing TB is low among health
care providers [10,21-23]. There is not any universally
accepted period for total delay from the onset of symp-
toms to the start of treatment for TB. Some authors have
suggested that this period should not exceed one month
[24], while others have suggested that a period of less than
two months is acceptable [14]. Despite the importance of
delay in the start of TB treatment, little is known about the
extent of the delay in Norway. In one study, a median
total delay of 15 weeks was found in 317 patients for
whom information on duration of symptoms was availa-
ble [25].
The aims of our study were to assess the delays in the start
of treatment for TB patients in Oslo/Akershus region, Nor-
way and to analyze risk factors for the delays.
Methods
Setting and study population
In Norway, there is compulsory nominative notification
of all TB cases to the National TB Registry (NTR). Both sus-
pected and confirmed cases have to be reported by clini-
cians. Laboratories of clinical microbiology are also
required to report all isolates of Mycobacterium tuberculosis
(M. tb). A total of 25 microbiological laboratories isolate
M. tb from patient samples. The laboratory of the Norwe-
gian Institute of Public Health functions as a national ref-
erence laboratory for TB. The pharmacy at the National
Hospital is the only pharmacy distributing drugs for TB
treatment, and it reports all TB prescriptions it handles to
the NTR. The notification is therefore considered to be
quite complete [26].
We identified the cases by reviewing notifications to the
NTR. Notification forms and lab data were also reviewed.
A total of 189 cases among persons aged 15 and above
were reported to the NTR from July 1, 2003 to February 6,
2004. Of these, 83 cases were reported from the main
Oslo and Akershus region hospitals and were included in
this study.
We estimated the onset of the first TB symptoms from
clinical case notes from hospitals and from referral case
notes from primary health care providers. In addition, we
have also reviewed the notification forms to the NTR.
For practical reasons, only information on delays in Nor-
way was considered, but the patients (seven patients) who
had delays abroad before arriving in Norway were
included in the study. For this group, information on
delays was considered from the arrival date in Norway.
Definition
Patient delay was defined as the period from onset of
symptoms related to TB to the date when the patient first
contacted health services for those symptoms. Health care
system delay was defined from the date of the patient's
first contact with the health services for those symptoms
to the date of the start of TB treatment. Total delay was
defined as the sum of the patient delay and the health care
system delay.
Definition
Pulmonary TB case refers to disease affecting the lung
parenchyma.  Extra-pulmonary TB case refers to TB out-
side the lung parenchyma. It is commonly found in the
mediastinal lymph nodes, larynx, cervical lymph nodes,
pleurae, meninges, central nervous system, spine, bones
and joints, kidneys, pericardium, intestines, peritoneum
and skin [27].
Statistical analysis
We used the statistical package SPSS, version 11.0. To cal-
culate the effect of variables such as sex, birthplace, site of
the disease and age group on patient delay, health care
system delay and total delay, we used multiple linear
regression analysis. The data for the delays were skewed.
Therefore, a logarithmic transformation was used to makeBMC Infectious Diseases 2006, 6:33 http://www.biomedcentral.com/1471-2334/6/33
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the data more normally distributed. P values of less than
0.05 were considered statistically significant.
This study received approval from the Regional Ethics
Committee for Medical Research, The Norwegian Data
Inspectorate and the Norwegian Directorate for Health
and Social Affairs.
Results
A total of 83 patients were included in this study. Of these,
71 were foreign-born (86%). The median and mean peri-
ods of residence in Norway for the foreign-born patients
were 2.5 and 5.1 years respectively. The median age for all
patients was 32 years. Among those born in Norway, the
median age was 57 years while among the foreign-born,
the median age was 30 years.
There were 57 pulmonary cases and 26 extra-pulmonary
cases. Of the 83 cases included in the study, 78 were new
cases and five were previously treated cases. Of the 57 pul-
monary cases, 52 were culture-positive, three were culture
negative and results were not known for two. Information
on smear status for pulmonary cases was available for 36
cases. Of these, 19 were smear-positive and 17 were
smear-negative.
Susceptibility testing for the main TB drugs was done for
most of the culture-positive patients (88%). Two patients
had multi-drug resistant TB (MDR-TB), i.e. resistance to
both isoniazid (INH) and rifampicin. Both were foreign-
born patients. An additional two patients had isolated
INH resistant strains.
The most frequent symptoms reported by the patients
were cough, fever and weight loss (Table 1). Other symp-
toms were night sweat and general malaise. For patients
with extra-pulmonary TB, the most frequent symptoms
were gland enlargement, headache and pain in the neck
and back.
For the patient, health care system and total delays there
were missing data for 21, 12 and 16 cases respectively. Of
the 83 cases included in this study, 61 cases had all the
information on patient, health care system and total
delays.
The median patient, health care system and total delays
for all patients were 28, 33 and 63 days respectively (Table
Table 1: Symptoms* reported by patients with pulmonary 
tuberculosis (N = 57)
Symptoms Number of patients (%)
Cough 42 (74%)
Productive 17 (30%)
Dry 25 (44%)
Weight loss 25 (44%)
Fever 20 (35%)
Night sweat 18 (32%)
Hemoptysis 9 (16%)
Dyspnea 11 (19%)
Chest pain 14 (25%)
General malaise 15 (26%)
Other 28 (49%)
No symptoms reported 5 (9%)
* For most patients, two or more symptoms were reported
Table 2: Patients characteristics for patient, health care system and total delays
N Patient delay Health care system delay Total delay
Median delay/ (range) in days*
Sex
Women 39 28/ (2–217) 35/ (2–182) 77/ (9–343)
Men 44 25/ (2–154) 22/ (1–378) 60/ (4–434)
Birthplace
Norway 12 21/ (3–84) 49/ (21–160) 56/ (35–147)
Abroad 71 28/ (2–217) 28/ (1–378) 67/ (4–434)
Site of the disease
Pulmonary 57 21/ (2–158) 22/ (1–378) 56/ (4–434)
Extra- pulmonary 26 42/ (10–217) 42/ (4–224) 81/ (14–378)
Age group
15–29 yrs 35 28/ (2–217) 35/ (1–224) 70/ (4–378)
30–44 yrs 29 28/ (3–158) 21/ (2–119) 49/ (16–259)
45–59 yrs 11 49/ (5–126) 53/ (4–378) 112/ (9–434)
60+ yrs 8 18/ (3–28) 49/ (25–70) 65/ (42–214)
All 83 28/ (2–217) 33/ (1–378) 63/ (4–434)
*Including missing dataBMC Infectious Diseases 2006, 6:33 http://www.biomedcentral.com/1471-2334/6/33
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2). Of the pulmonary cases, the median patient, health
care system and total delays were 21, 22 and 56 days
respectively. For the extra-pulmonary cases, the median
patient, health care system and total delays were 42, 42
and 81 days respectively. The median health care system
delay was longer than patient delay in patients born in
Norway.
For those with information on smear status, the median
delays for patient, health care system and total for smear-
positive pulmonary cases were 28, 14 and 45 days respec-
tively. For the smear-negative pulmonary cases, the
median patient, health care system and total delays were
14, 46 and 60 days.
The site of the disease was the only significant predictor of
both patient, health care system and total delay in unad-
justed and adjusted analysis, with delays in patients with
extra-pulmonary TB varying from two to three times the
delays in patients with pulmonary disease (Table 3). The
age group 60+ years had significantly shorter patient delay
than the reference group aged 15–29 years when adjusted
for multiple covariates. Also, in the multivariate analysis
patients born abroad had significantly shorter health care
system delays than patients born in Norway.
Of the 83 patients included in the study, 66 patients were
hospitalized before start of treatment. The median and
mean period between hospital admission and treatment
start for those hospitalized before start of the TB treatment
was 4 (1–82) and 18 days, respectively.
Of the 37 TB cases with more than two months of total
delay, 20 were pulmonary cases and 17 were extra-pulmo-
nary cases. Of these 33 (89%) were born abroad, whereas
86 % of all cases were foreign-born.
We have studied in detail 15 of the 37 patients with a total 
delay of more than two months, for whom more specific 
information was available
1. Nine patients had received several courses of antibiotics
from primary health care providers before the start of TB
treatment. Some had family members with a history of
previous TB. They were sent for further examination at the
hospital only after the courses of antibiotics did not help.
Table 3: Relative treatment delays estimated by the exponential of regression coefficients from multiple linear regression. Dependent 
variables: log (patient delay), log (health care system delay) and log (total delay).  (95 % confidence intervals)
Patient delay Health care system delay Total delay
Univariate Multivariate† Univariate Multivariate Univariate Multivariate
Relative delay Relative delay Relative delay Relative delay Relative delay Relative delay
Sex
Women‡ 1.00 1.00 1.00 1.00 1.00 1.00
Men 0.68 
(0.37–1.27)
0.71 
(0.39–1.29)
0.76 
(0.44–1.34)
0.84 
(0.49–1.45)
0.77 
(0.48–1.24)
0.81 
(0.50–1.29)
Birthplace
Norway‡ 1.00 1.00 1.00 1.00 1.00 1.00
Abroad 1.26 
(0.44–3.62)
0.56 
(0.17–1.89)
0.46 
(0.19–1.12)
0.32 
(0.11–0.94)
0.94 
(0.47–1.88)
0.81 
(0.37–1.78)
Site of the disease
Pulmonary‡ 1.00 1.00 1.00 1.00 1.00 1.00
Extra-
pulmonary
2.44 
(1.31–4.54)
2.97 
(1.57–5.61)
1.92 
(1.08–3.42)
2.04 
(1.13–3.68)
1.80 
(1.11-2.91)
1.81 
(1.10–2.98)
Age group
15–29 yrs‡ 1.00 1.00 1.00 1.00 1.00 1.00
30–44 yrs 0.99 
(0.49–2.02)
0.94 
(0.48–1.82)
0.60 
(0.33–1.12)
0.61 
(0.34–1.10)
0.79 
(0.47–1.35)
0.80 
(0.47–1.35)
45–59 yrs 1.69 
(0.66–4.38)
1.90 
(0.79–4.58)
1.54 
(0.61–3.85)
1.70 
(0.70–4.13)
1.52 
(0.72–3.20)
1.59 
(0.77–3.28)
60+ yrs 0.55 
(0.15–2.10)
0.21 
(0.05–0.99)
1.40 
(0.46–4.27)
0.41 
(0.10–1.63)
1.13 
(0.47–2.70)
0.87 
(0.32–2.35)
†In the multivariate analysis, all variables in the univariate analysis were included.
‡ Reference category.BMC Infectious Diseases 2006, 6:33 http://www.biomedcentral.com/1471-2334/6/33
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2. Four patients had long total delay mainly due to diffi-
culties in isolating bacilli, difficulties in making TB diag-
nosis and negative results of the initial tests done (sputum
and x-ray were negative). For some, the x-ray did not give
a clear indication for TB.
3. Two patients had concomitant diseases such as asthma
and Morbus Crohn that caused delays in suspecting TB
disease.
All 15 patients, except one, were born abroad. Thirteen
came from countries with a high prevalence of TB. The
majority of all TB patients in this study were born abroad.
Thus, even though those patients born abroad had shorter
health care system delays, most patients with long total
delays were also born abroad.
We have also studied in detail 4 of the 14 patients with less 
than one month total delay, for whom more specific 
information was available
1. There was suspicion of TB when the patient first visited
the primary health care provider. Still, the patient was first
treated with antibiotics for presumed pneumonia.
2. The delay was short because the patient had been
treated for TB before and also had symptoms related to
TB.
3. The patient was admitted to the hospital for other rea-
son than TB disease. There was no history of TB in the
family, but an x-ray suggested TB.
4. At hospital admission, there was a strong suspicion of
TB due to the patient's country of origin (a high TB preva-
lence country) and previous TB in the family.
Discussion
Our study has indicated a median total delay of 63 days
from the onset of symptoms to the start of TB treatment
for all 83 patients. In our study, the median health care
system delay for all patients included in the study
exceeded the median patient delay. But among those born
in Norway, health care system delay was more than twice
as long as patient delay. Many studies have found that
patient delays were longer than health care system delays
[28,29]. Other studies have found the opposite
[18,30,31]. The main reason for the delay in the studies in
which the health care system delay was longer than the
patient delay was failure of accurate diagnosis at the initial
presentation. In our study, the main reason for the long
total delay was that the health care providers did not ini-
tiate specific TB examination despite symptoms such as
cough, weight loss and night sweat. TB examination was
initiated only after unsuccessful antibiotics treatment.
Some patients had other diseases such as asthma that
made it more difficult to suspect TB.
The health care system delay for those born in Norway
was twice as long as for those born abroad. One reason for
the longer health care system delay for those born in Nor-
way could be that the index of suspicion for TB might be
lower for this group, since TB incidence among those born
in Norway is low. Some studies from other low TB preva-
lence countries have shown that there is a greater aware-
ness among health care providers of the risk of TB for
those born abroad [32,33].
Most TB patients born in Norway are in older age. Many
of them have co-existing illness. This makes TB diagnosis
difficult and thus causes delay [34,35]. Older patients may
present with respiratory symptoms less often than
younger patients [21,28,34-37]. This also explains why
the condition of many of the older patients could deterio-
rate without TB being considered. Awareness for TB is
needed for this group.
Some reasons that might explain the longer patient delays
for those born abroad are stigma, fear of deportation, lack
of TB knowledge, language problems and cultural differ-
ences in the interpretation of signs and symptoms [38].
Some authors have suggested that social and cultural fac-
tors may influence patients' decision to seek help. In
many cultures, the patient's problem is compounded by
the social stigma of TB, a fear that may contribute to a long
delay in seeking professional care and even to abandon-
ment of treatment [39]. In our study, 86% of the patients
were foreign-born and the majority of them came from
countries with high TB prevalence, in which stigma may
play a major role.
In the multiple regression analysis for patient, health care
and total delay, extra-pulmonary site was the only factor
that was significant in both univariate and multivariate
analysis. It was not surprising that patients with pulmo-
nary TB had shorter delay than patients with extra-pulmo-
nary TB. Patients with extra-pulmonary TB may have a
variety of symptoms and are difficult to diagnose. In our
study, 17 of the 37 TB cases with more than two months
of total delay were extra-pulmonary TB cases. From a pub-
lic health perspective, these cases have less consequence
for the spread of the disease, as cases of extra-pulmonary
TB are rarely infectious. However, they may cause a diag-
nostic challenge for health personnel and could easily be
overlooked. For the patients, delay in the start of TB treat-
ment can result in increased severity and mortality
[40,41]. But as shown in our study, there were several
cases with pulmonary TB, some with symptoms such as
cough, weight loss and night sweat that had total delays of
more than 90 days.BMC Infectious Diseases 2006, 6:33 http://www.biomedcentral.com/1471-2334/6/33
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In our study, we have investigated the median time
between hospital admission and the start of TB treatment.
Although the data were not complete, we found that
around 80% of the patients included in this study were
hospitalized before the start of TB treatment. The median
time between hospitalization and the start of TB treatment
was four days (1–82). Studies from Washington, DC,
United States of America (USA) and St. Louis, USA have
also found a median time of six days between the hospi-
talization and the start of TB treatment [34,42]. In these
studies, delays in the start of TB treatment were longer
than delays in the initial suspicion of TB. It was also the
case even for patients with smear-positive disease. This
was explained by the fact that health care providers waited
for confirmation by culture results. Delaying the start of
TB treatment could increase transmission and mortality of
TB, but early initiation of treatment without culture verifi-
cation might carry the risk of starting treatment on the
basis of a wrong diagnosis [43,44]. In our study, only
three patients had no information about culture status.
According to the new Norwegian manual for TB control
and prevention [6], it is recommended that treatment
could either be started on clinical suspicion of TB or one
can wait for culture results if sputum smear result is nega-
tive. In our study, some health care providers may have
taken the latter approach. It explains also that smear-neg-
ative pulmonary cases had longer health care system delay
compared to smear-positive cases. In our study, the
median health care system delay for smear-positive pul-
monary cases was 14 days.
An advantage of our study was that we have analyzed
delays for both pulmonary TB and extra-pulmonary TB
cases. Most studies that have studied delays have evalu-
ated delays for pulmonary TB only. The two sites of the
disease are different with regard to symptoms and diagno-
sis. However, both reflect the circulation of the M. tb in
the population.
One limitation of our study was that primary health care
and hospital notes were often incomplete regarding
delays, especially for the patient delay. For some patients,
the referral letter was missing. This made it difficult to find
the exact date when the patient first contacted a health
care provider for symptoms related to TB. Since we have
collected the date of the onset of symptoms from different
sources, there was a potential for discrepancies in the esti-
mated dates for individual patients. We have made efforts
to minimize these potential discrepancies by validating
the data through different sources for each patient. Data
on delays were missing for some cases. This could influ-
ence the results of our study. But when we evaluated sep-
arately all cases with complete information on delays (61
cases) and all cases included in the study with missing
data on same types of delay (83 cases), the univariate and
multivariate analysis for both gave similar results. So the
missing data on same types of delay did not affect the
overall results of this study. Another limitation was that
we used only the delays in Norway for some foreign-born
(seven patients) for practical reasons. They were included
in the study, but the data for delays abroad were not
included. Although this affected very few cases, it is possi-
ble that we have underestimated the actual delays for this
group.
Conclusion
A high proportion of patients had total delays in start of
TB treatment exceeding two months. This study empha-
sizes the need of awareness of TB in the general popula-
tion and among health personnel. Extra-pulmonary TB
should be considered as a differential diagnosis in unre-
solved cases, especially for immigrants from high TB prev-
alence countries.
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